1. ScholarBank@NUS

Thuan Heng, Charles Chuah

rp07456

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Thuan Heng, Charles Chuah
Variants
Chuah, C.
Chuah, Charles T.H.
 
Main Affiliation
 
Faculty
 
Email
gmscthc@nus.edu.sg
 

Publications

Results 1-14 of 14 (Search time: 0.009 seconds).

Issue DateTitleAuthor(s)
12013A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasCortes, J.E.; Kim, D.-W.; Pinilla-Ibarz, J.; Le Coutre, P.; Paquette, R.; Chuah, C. ; Nicolini, F.E.; Apperley, J.F.; Khoury, H.J.; Talpaz, M.; DiPersio, J.; DeAngelo, D.J.; Abruzzese, E.; Rea, D.; Baccarani, M.; Müller, M.C.; Gambacorti-Passerini, C.; Wong, S.; Lustgarten, S.; Rivera, V.M.; Clackson, T.; Turner, C.D.; Haluska, F.G.; Guilhot, F.; Deininger, M.W.; Hochhaus, A.; Hughes, T.; Goldman, J.M.; Shah, N.P.; Kantarjian, H.
217-Nov-2011Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasNicolini, F.E.; Basak, G.W.; Soverini, S.; Martinelli, G.; Mauro, M.J.; Müller, M.C.; Hochhaus, A.; Chuah, C. ; Dufva, I.H.; Rege-Cambrin, G.; Saglio, G.; Michallet, M.; Labussière, H.; Morisset, S.; Hayette, S.; Etienne, G.; Olavarria, E.; Zhou, W.; Peter, S.; Apperley, J.F.; Cortes, J.
32014Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adultsKrishnan, S.; Sabai, K.; Chuah, C. ; Tan, S.Y.
419-Jun-2018BIM Deletion Polymorphism Profiling Complements Prognostic Values of Risk Scores in Imatinib-treated Asian Chronic Myeloid Leukemia PatientsHein Than; Weng Kit Lye ; Colin Sng; John Allen, S. ; Tiong Ong ; Charles Chuah 
523-Jan-2014Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Jabbour, E.; Kantarjian, H.M.; Saglio, G.; Steegmann, J.L.; Shah, N.P.; Boqué, C.; Chuah, C. ; Pavlovsky, C.; Mayer, J.; Cortes, J.; Baccarani, M.; Kim, D.-W.; Bradley-Garelik, M.B.; Mohamed, H.; Wildgust, M.; Hochhaus, A.
61-Sep-2021Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T CellsLee, Wen-Hsin Sandy; Ye, Zhiyong; Cheung, Alice MS; Goh, YP Sharon; Oh, Hsueh Ling Janice; Rajarethinam, Ravisankar; Yeo, Siok Ping; Soh, Mun Kuen; Li Chan, Esther Hian; Tan, Lip Kun; Tan, Soo-Yong ; Chuah, Charles ; Chng, Wee Joo ; Connolly, John E; Wang, Cheng-I
72015High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCR-capillary gel electrophoresisRamlee, M.K; Yan, T ; Cheung, A.M.S ; Chuah, C.T.H ; Li, S 
827-Sep-2012Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutationCortes, J.; Lipton, J.H.; Rea, D.; Digumarti, R.; Chuah, C. ; Nanda, N.; Benichou, A.-C.; Craig, A.R.; Michallet, M.; Nicolini, F.E.; Kantarjian, H.
92014Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibitionNg K.P. ; Manjeri A. ; Lee K.L. ; Huang W. ; Tan S.Y. ; Chuah C.T.H. ; Poellinger L. ; Ong S.T. 
102015Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respirationXiang W.; Cheong J.K. ; Ang S.H. ; Teo B.; Xu P. ; Asari K.; Sun W.T. ; Than H.; Bunte R.M. ; Virshup D.M. ; Chuah C. 
112018The arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional targetNg K.P. ; Manjeri A. ; Lee L.M. ; Chan Z.E. ; Tan C.Y.; Tan Q.D. ; Majeed A. ; Lee K.L. ; Chuah C. ; Suda T. ; Ong S.T. 
122014The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsKo T.K. ; Chuah C.T. ; Huang J.W.; Ng K.-P. ; Ong S.T. 
132016The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemiaKo T.K. ; Chin H.S. ; Chuah C.T.H. ; Huang J.W.J.; Ng K.-P. ; Khaw S.L.; Huang D.C.S.; Ong S.T.
142017The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemiaRauzan M. ; Chuah C.T.H. ; Ko T.K. ; Tiong Ong S.